{"entity":{"id":"nct01081951","kind":"trial","name":"Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitax","aka":[],"tldr":"A phase 2 trial of Olaparib, Paclitaxel / nab-paclitaxel, Carboplatin in ovarian cancer, run by AstraZeneca, active and no longer recruiting.","summary":"Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer is a phase 2 interventional study registered as NCT01081951 by AstraZeneca, with 162 participants enrolled, started 2010-02-04 and due to reach its primary completion in 2011-10-10. Interventions recorded: olaparib, paclitaxel, carboplatin, paclitaxel, Drug: carboplatin. Conditions listed: Ovarian Cancer. Results were posted on ClinicalTrials.gov in 2012; the figures recorded here are the registry's, not a publication's.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT01081951","url":"https://clinicaltrials.gov/study/NCT01081951"}],"tags":["ctgov-ingest"],"related":[],"cancers":["ovarian","platinum-sensitive-ovarian-cancer"],"sections":[],"technologies":["cytotoxic-chemotherapy","parp-inhibitor","platinum"],"targets":[],"drugs":["olaparib","paclitaxel","carboplatin"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT01081951","phase":"2","setting":"A Phase II Open Label Randomised Comparative Multicentre Study to Compare the Efficacy and Tolerability of Olaparib in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Patients With Platinum Sensitive Advanced Serous Ovarian Cancer","sponsor":"AstraZeneca","started":"2010-02-04","startedType":"actual","yearReported":2012,"enrolled":162,"enrolledBasis":"registry","outcomes":[{"endpoint":"Progression Free Survival (PFS)","primary":true,"unit":"months","arms":[{"name":"Olaparib/Carboplatin AUC4/Paclitaxel","n":81,"value":12.2,"note":"95% CI 9.7 to 15.0; Figures from the ClinicalTrials.gov results section (first posted 2012-12-10), not from a publication"},{"name":"Carboplatin AUC6/Paclitaxel","n":81,"value":9.6,"note":"95% CI 9.1 to 9.7"}],"hr":0.51,"ci":[0.34,0.77],"p":"0.0012","source":"https://clinicaltrials.gov/study/NCT01081951?tab=results"},{"endpoint":"Overall Survival (OS)","unit":"participants (number of deaths)","arms":[{"name":"Olaparib/Carboplatin AUC4/Paclitaxel","n":81,"value":54,"note":"Figures from the ClinicalTrials.gov results section (first posted 2012-12-10), not from a publication"},{"name":"Carboplatin AUC6/Paclitaxel","n":81,"value":47}],"hr":1.17,"ci":[0.79,1.73],"p":"0.4379","source":"https://clinicaltrials.gov/study/NCT01081951?tab=results"}]},"route":"/trials/nct01081951/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"platinum-sensitive-ovarian-cancer","kind":"cancer","name":"Platinum-sensitive ovarian cancer","route":"/cancers/platinum-sensitive-ovarian-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"parp-inhibitor","kind":"technology","name":"PARP inhibitors","route":"/technologies/parp-inhibitor/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}